Participated · Seed · May 2026

Scarlet Therapeutics develops red blood cell therapies produced from immortalized cell lines to create scalable, off-the-shelf biologic products. Its lab-grown RBCs have, in preclinical studies, matured and circulated in vivo with a half-life comparable to donated red blood cells. The company modifies RBCs to convert toxic metabolites and is targeting indications including hyperammonemia and hyperoxaluria. Because it uses immortalized master cell banks, Scarlet aims to avoid donor-sourced scalability and reproducibility issues and to manufacture at large scale. Scarlet plans quarterly dosing of its RBC products and is advancing process development and regulatory interactions to support a clinical path. The recent £3.2 million seed raise will fund animal studies in three indications and help position the company for a follow-on financing once a lead program is selected.

Led · Series A · Dec 2025

MitoRx Therapeutics operates as a platform biotech focused on translating mitochondrial biology into novel therapeutics for obesity and broader metabolic disorders. Its lead candidates are innovative small-molecule metabolic modulators designed to induce weight loss without compromising muscle integrity, a key differentiator in the crowded obesity-drug landscape. The company is currently at the preclinical stage and is building a pipeline around these modulators. With its recent pre-seed capital raise of roughly $7.3 million, MitoRx will accelerate preclinical validation studies, prepare for future regulatory submissions, and expand both its scientific team and laboratory infrastructure. Management plans to deploy the funds toward advancing its lead programs through early development milestones. Although still pre-revenue, the influx of capital signifies investor confidence in the company’s scientific approach and commercial potential. MitoRx’s near-term objectives include scaling its research footprint and progressing toward clinical readiness. Over the longer term, it aims to deliver differentiated treatments that improve metabolic health and preserve muscle mass in millions of patients.

Led · Series A · Jul 2024

4D Medicine, founded in 2020 as a spin-out from the Universities of Birmingham and Warwick and based in Nottingham, develops a resorbable biomaterial called 4Degra for medical implants. 4Degra degrades gradually from the surface without producing harmful acidic by-products and can be 3D-printed in both soft and hard formulations. The material is being developed into implants ranging from flexible films and membranes to rigid plates, pins and bone scaffolds. The company plans to complete pre-clinical testing of its first medical device product range and to seek FDA clearance to enter the US market. Management is preparing to close a Series B early next year; total funding to date is £5M. 4D Biomaterials has developed 4Degra, a biodegradable 3D-printed material that can be printed to exact shapes as an open cell honeycomb structure to improve patient outcomes. The structure allows natural tissue to grow through voids as the material gradually erodes and is expelled by the body. 4Degra was developed over more than 15 years in Professor Andrew Dove's research group at the University of Warwick and University of Birmingham, and the company spun out of those universities last year. The company says the material could be used in applications including tumour removal in breast cancer patients and recovery from other surgery and trauma. 4D Biomaterials appointed Phil Smith as CEO and plans to develop a range of products through partnerships with medical device companies. The recent funding will also support team expansion and the creation of five jobs at its MediCity premises.

Led · Equity · Jun 2024

Topadur Pharma AG is developing TOP-M119, a drug candidate with a novel mode of action for treating androgenic alopecia. Pre-clinical studies reported that TOP-M119 demonstrated higher potency, a faster onset of action and improved local tolerability compared with the standard of care. The company is advancing a liquid topical formulation and is also working on intradermal sustained‑release formulations for medical‑cosmetic applications targeting alopecia and skin ageing. Topadur has signed a co‑development, licensing and commercialization agreement for Greater China to accelerate development and patient access. The partnership initially focuses on completing IND studies and clinical phases I and II. The deal includes an upfront CHF 3 million investment and milestone payments totalling CHF 12 million to cover the estimated development costs. Market context in the article notes the global alopecia market was valued at USD 8.8 billion in 2023 and is projected to exceed USD 16 billion by 2030. Topadur develops drug candidates for severe wounds, including diabetic foot ulcer, chronic wounds, scars and keloids. Its lead R&D programs are locally active, highly potent and employ a dual mode of action the company says offers higher than average clinical success chances. The team aims to improve patients' quality of life and address a large unmet medical need—diabetic foot ulcers and chronic wounds drive hospitalizations, amputations, and more than €10 billion in annual costs. Topadur traces its roots to TOPADUR GmbH (formed in 2010) and its leadership combines substantial pharmaceutical development experience across marketed products. Financially, the company closed an oversubscribed CHF2.2 million Series A and also secured CHF1.2 million in CTI and Eurostars grants to advance development. Management says the proceeds and grants will allow them to move development of their unique drug candidates a significant step forward.